A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PI3Kdelta

Search Conditions:
Search Keyword : PI3Kdelta
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: PI3Kdelta
Appearance Frequency: 85 time(s)
Long forms: 8

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
phosphoinositide 3-kinase delta
(77 times)
Pharmacology
(15 times)
CLL (12 times)
COPD (6 times)
AEs (4 times)
2009 Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma.
Phosphoinositol-3 kinase delta
(2 times)
Immune System Diseases
(1 time)
CCR5 (1 time)
DPP-4 (1 time)
2014 Characterization of Novel PI3Kdelta Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies.
phosphatidylinositol 3-kinase isoform p110delta
(1 time)
Allergy and Immunology
(1 time)
BCR (1 time)
BTK (1 time)
Syk (1 time)
2013 B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(1 time)
Drug Therapy
(1 time)
B-ALL (1 time)
CLL (1 time)
2014 Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
phosphatidylinositol-3-OH kinase catalytic subunit p110delta
(1 time)
Allergy and Immunology
(1 time)
GC (1 time)
2018 Hyperactivated PI3Kdelta promotes self and commensal reactivity at the expense of optimal humoral immunity.
Phosphatidylinositol-4,5-bisphosphate 3-kinase delta
(1 time)
Neoplasms
(1 time)
18F-FLT-PET (1 time)
ABC (1 time)
BCR (1 time)
2017 Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.
phosphoinositide 3-kinase delta-isoform
(1 time)
Allergy and Immunology
(1 time)
BCR (1 time)
BTK (1 time)
Syk (1 time)
2013 New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.
PI3K p110 isoform delta
(1 time)
Neoplasms
(1 time)
--- 2015 Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.